- Home
- ALGS vs CLSD Comparison
ALGS vs CLSD Comparison
Compare ALGS & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- CLSD
- Stock Information
- Founded
- ALGS 2018
- CLSD 2011
- Country
- ALGS United States
- CLSD United States
- Employees
- ALGS N/A
- CLSD N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- CLSD Health Care
- Exchange
- ALGS Nasdaq
- CLSD Nasdaq
- Market Cap
- ALGS 50.4M
- CLSD 59.1M
- IPO Year
- ALGS 2020
- CLSD 2016
- Fundamental
- Price
- ALGS $7.84
- CLSD $0.81
- Analyst Decision
- ALGS Strong Buy
- CLSD Strong Buy
- Analyst Count
- ALGS 1
- CLSD 5
- Target Price
- ALGS $70.00
- CLSD $4.80
- AVG Volume (30 Days)
- ALGS 125.8K
- CLSD 402.9K
- Earning Date
- ALGS 08-05-2025
- CLSD 08-11-2025
- Dividend Yield
- ALGS N/A
- CLSD N/A
- EPS Growth
- ALGS N/A
- CLSD N/A
- EPS
- ALGS N/A
- CLSD N/A
- Revenue
- ALGS $3,270,000.00
- CLSD $3,764,000.00
- Revenue This Year
- ALGS N/A
- CLSD $60.52
- Revenue Next Year
- ALGS $51.55
- CLSD $88.28
- P/E Ratio
- ALGS N/A
- CLSD N/A
- Revenue Growth
- ALGS N/A
- CLSD N/A
- 52 Week Low
- ALGS $3.76
- CLSD $0.70
- 52 Week High
- ALGS $46.80
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- ALGS 57.02
- CLSD 50.66
- Support Level
- ALGS $6.82
- CLSD $0.79
- Resistance Level
- ALGS $8.66
- CLSD $0.82
- Average True Range (ATR)
- ALGS 0.76
- CLSD 0.04
- MACD
- ALGS -0.06
- CLSD 0.00
- Stochastic Oscillator
- ALGS 55.49
- CLSD 52.88
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.